ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0857

Agreement of Hydroxychloroquine Blood Levels Between a University and Commercial Laboratory
Abstract Number: 0138

Alignment and Discordances in Treatment Perceptions and Shared Decision-Making Among RA Patients and Rheumatology Care Teams
Abstract Number: 2046

Alterations in Circulating CD4+ T Cell Phenotypes in CCP+ Early RA and CCP+ At-risk Individuals by Mass Cytometry
Abstract Number: 1083

Alterations of Lipid Profile in IIM Patients Are Associated with Disease Activity, Duration, and Glucocorticoid Treatment
Abstract Number: 1819

Altered Brain Functional Connectivity in Systemic Lupus Erythematosus
Abstract Number: 0959

Altered Gut Microbiome in Dermatomyositis
Abstract Number: 0387

Altered Iron Homeostasis and Pulmonary Haemodynamics in Systemic Sclerosis Associated Pulmonary Arterial Hypertension
Abstract Number: 1449

Altered Splicing in Leukocytes from Patients with Antiphospholipid Syndrome, Systemic Lupus Erythematosus and Antiphospholipid Syndrome with Lupus: Clinical Involvement
Abstract Number: 0711

Alternative Dosing of Biologic Therapies Is Frequent Among Children with Juvenile Idiopathic Arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry
Abstract Number: 1836

Alternative Renal Response Definitions in a Randomized, Controlled Trial of Obinutuzumab for Proliferative Lupus Nephritis
Abstract Number: 0840

Amelioration of Immune Complex-Mediated Glomerulonephritis via CD6 Modulation
Abstract Number: 0066

AMP Deaminase 2 Is Expressed on the Surface of Human Immune Cells as a Novel Regulator of Extracellular Adenosine Metabolism
Abstract Number: 1545

An Artificial Intelligence (AI) Assistant Identifying Spinal Diffuse Idiopathic Skeletal Hyperostosis on Plain X-rays: A Pilot Deep Learning Study
Abstract Number: 1801

An Engineered Extracellular Matrix‐rich Decellularized Substrate Based Podocytes Culture System to Study Intracellular Complement Production and Activation
Abstract Number: 1429

An Evaluation of Real World Use of Biologics in Rare Systemic Vasculitides During Routine Clinical Care in the US

« Previous Page
1
…
6
7
8
9
10
…
139
Next Page »

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].